These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 26731722)

  • 1. Diabetes and Body Mass Index Are Associated with Neuropathy and Prognosis in Colon Cancer Patients Treated with Capecitabine and Oxaliplatin Adjuvant Chemotherapy.
    Ottaiano A; Nappi A; Tafuto S; Nasti G; De Divitiis C; Romano C; Cassata A; Casaretti R; Silvestro L; Avallone A; Capuozzo M; Capozzi M; Maiolino P; Quagliariello V; Scala S; Iaffaioli VR
    Oncology; 2016; 90(1):36-42. PubMed ID: 26731722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102).
    Miyamoto Y; Tsuji A; Tanioka H; Maekawa S; Kawanaka H; Kitazono M; Oki E; Emi Y; Murakami H; Ogata Y; Saeki H; Shimokawa M; Natsugoe S; Akagi Y; Baba H; Maehara Y
    Int J Clin Oncol; 2016 Aug; 21(4):705-712. PubMed ID: 26746689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High Resectability Rate of Initially Unresectable Colorectal Liver Metastases After UGT1A1-Adapted High-Dose Irinotecan Combined with LV5FU2 and Cetuximab: A Multicenter Phase II Study (ERBIFORT).
    Phelip JM; Mineur L; De la Fouchardière C; Chatelut E; Quesada JL; Roblin X; Pezet D; Mendoza C; Buc E; Rivoire M
    Ann Surg Oncol; 2016 Jul; 23(7):2161-6. PubMed ID: 26739304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determining the Optimal Timing for Initiation of Adjuvant Chemotherapy After Resection for Stage II and III Colon Cancer.
    Sun Z; Adam MA; Kim J; Nussbaum DP; Benrashid E; Mantyh CR; Migaly J
    Dis Colon Rectum; 2016 Feb; 59(2):87-93. PubMed ID: 26734965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer.
    Chibaudel B; Maindrault-Gœbel F; Bachet JB; Louvet C; Khalil A; Dupuis O; Hammel P; Garcia ML; Bennamoun M; Brusquant D; Tournigand C; André T; Arbaud C; Larsen AK; Wang YW; Yeh CG; Bonnetain F; de Gramont A
    Cancer Med; 2016 Apr; 5(4):676-83. PubMed ID: 26806397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of comorbidity on the use of adjuvant chemotherapy and type of regimen for curatively resected stage III colon cancer patients.
    Hsieh MC; Thompson T; Wu XC; Styles T; O'Flarity MB; Morris CR; Chen VW
    Cancer Med; 2016 May; 5(5):871-80. PubMed ID: 26773804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluorouracil-based preoperative chemoradiotherapy with or without oxaliplatin for stage II/III rectal cancer: a 3-year follow-up study.
    Jiao D; Zhang R; Gong Z; Liu F; Chen Y; Yu Q; Sun L; Duan H; Zhu S; Liu F; Wang J; Jia J
    Chin J Cancer Res; 2015 Dec; 27(6):588-96. PubMed ID: 26752933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Capecitabine-Induced Severe Toxicity Secondary to DPD Deficiency and Successful Treatment with Low Dose 5-Fluorouracil.
    Kodali S; Bathini V; Rava P; Tipirneni E
    J Gastrointest Cancer; 2017 Mar; 48(1):66-69. PubMed ID: 26744322
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer.
    Wang ZQ; Zhang DS; Xu N; Luo DY; Deng YH; Wang FH; Luo HY; Qiu MZ; Li YH; Xu RH
    Chin J Cancer; 2016 Jan; 35():8. PubMed ID: 26739998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence, severity, longitudinal trends and predictors of acute and chronic oxaliplatin-induced peripheral neuropathy in Taiwanese patients with colorectal cancer.
    Hsu SY; Huang WS; Lee SH; Chu TP; Lin YC; Lu CH; Beaton RD; Jane SW
    Eur J Cancer Care (Engl); 2019 Mar; 28(2):e12976. PubMed ID: 30536809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association of clinical and patient factors with chemotherapy-induced peripheral neuropathy (CIPN) in colorectal cancer: secondary analysis of the SCOT trial.
    Lemanska A; Harkin A; Iveson T; Kelly C; Saunders M; Faithfull S
    ESMO Open; 2023 Dec; 8(6):102063. PubMed ID: 37988949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does statin suppress oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer? A single-center observational study.
    Okamoto K; Nozawa H; Emoto S; Murono K; Sasaki K; Ishihara S
    Support Care Cancer; 2023 Oct; 31(12):660. PubMed ID: 37897532
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    McEvoy L; Cliff J; Carr DF; Jorgensen A; Lord R; Pirmohamed M
    Front Pharmacol; 2023; 14():1178421. PubMed ID: 37469869
    [No Abstract]   [Full Text] [Related]  

  • 14. Patient Characteristics Associated With Chemotherapy-Induced Peripheral Neuropathy Severity in a Phase II Clinical Trial: A Retrospective Analysis.
    Zhi WI; Dreyfus N; Lessing A; Galantino M; Piulson L; Kot KL; Li S; Bao T
    Oncologist; 2023 Jul; 28(7):604-608. PubMed ID: 36972359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of Diabetes Mellitus on Oncological Outcomes for Patients Living With Cancer.
    Murphy L; Sherifali D; Ali MU; Ibrahim S
    Sci Diabetes Self Manag Care; 2023 Apr; 49(2):163-179. PubMed ID: 36789641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management.
    Pati S; Irfan W; Jameel A; Ahmed S; Shahid RK
    Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential Mediators of Oxaliplatin-Induced Peripheral Neuropathy From Adjuvant Therapy in Stage III Colon Cancer: Findings From CALGB (Alliance)/SWOG 80702.
    Lee S; Ma C; Shi Q; Kumar P; Couture F; Kuebler P; Krishnamurthi S; Lewis D; Tan B; Goldberg RM; Venook A; Blanke C; O'Reilly EM; Shields AF; Meyerhardt JA
    J Clin Oncol; 2023 Feb; 41(5):1079-1091. PubMed ID: 36367997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The metabolic syndrome and its components as prognostic factors in colorectal cancer: A meta-analysis and systematic review.
    Lu B; Qian JM; Li JN
    J Gastroenterol Hepatol; 2023 Feb; 38(2):187-196. PubMed ID: 36287138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group Neurotoxicity Questionnaire for the Latin American Population.
    Ribeiro IL; Lorca LA; Cuevas-Cid R; Dixit S; Yáñez-Benavides N; Ortega-Gonzalez F
    Int J Breast Cancer; 2022; 2022():6533797. PubMed ID: 36124163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors influencing downstaging after neoadjuvant long-course chemoradiotherapy in rectal carcinoma.
    Kohl VKB; Weber K; Brunner M; Geppert CI; Fietkau R; Grützmann R; Semrau S; Merkel S
    Int J Colorectal Dis; 2022 Jun; 37(6):1355-1365. PubMed ID: 35545701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.